LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

Published Date: 21 Nov 2025

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot